Poteligeo

Product manufactured by Kyowa Kirin, Inc.

Application Nr Approved Date Route Status External Links
BLA761051 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Poteligeo Is Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Mycosis Fungoides (Mf) Or Sézary Syndrome (Ss) After At Least One Prior Systemic Therapy. Poteligeo Is A Cc Chemokine Receptor Type 4 (Ccr4)-Directed Monoclonal Antibody Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Mycosis Fungoides Or Sézary Syndrome After At Least One Prior Systemic Therapy [ 1 ].

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Mogamulizumab

Comments